Inflammatory disease of the upper respiratory region is exceedingly common and in a considerable portion of the patients hemolytic streptococci are present on the mucous membrane in abundance and are evidently etiologically related to the disorder. When the infection extends to the middle ear, the mastoid, the bronchi and the adjacent parenchyma of the lung or to the blood stream, one is not infrequently able to detect streptococci in pure culture in these new situations, a circumstance which offers strong evidence implicating the streptococcus as an important inflammatory agent at the original site, where it had been associated with other microbes. The use of streptococcus serum in the treatment of infections of the upper respiratory tract seems to have been somewhat neglected, except when these inflammations have been associated with the clinical manifestations leading to a diagnosis of erysipelas or of scarlet fever. We are inclined to a somewhat different
SHEPLAR AE, SPENCE MJ, MacNEAL WJ. THERAPEUTIC USE OF THE CONCENTRATED STREPTOCOCCUS SERUM OF THE NEW YORK STATE DEPARTMENT OF HEALTH: IN PATIENTS WITH INFECTIONS OF THE EAR, NOSE AND THROAT. Arch Surg. 1935;30(1):1–13. doi:10.1001/archsurg.1935.01180070004001
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: